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ANAEROBIC WASTEWATER TREATMENT FOR  
REMOVAL OF PHARMACEUTICAL RESIDUES 
Kaitlin Ramsay,  Ania Escudero, Ole Pahl, Colin Hunter, Moyra McNaughtan 
Contact email: Kaitlin.Ramsay@gcu.ac.uk or Ania.Escudero@gcu.ac.uk 
INTRODUCTION 
Pharmaceutical residues (PR) generally originate from urban- 
environments, despite partial removal in traditional wastewater 
treatment systems, they may reach the natural aquatic environment 
(Figure1) at concentrations up to µg/L. Although these concentrations 
are unlikely to affect human health, they can cause chronic exposure 
damage to aquatic organisms. Anaerobic digestion (AD) is a potential 
tertiary treatment stage used to clean up pharmaceutical containing 
sewage but like any biological process AD can be effected by the 
presence of PR. The principal aim of this work was to investigate the 












Figure 1. Occurrence of pharmaceuticals in the environment 
METHODOLOGY 
Experimental design 
To assess the inhibition of bacteria and biomethanization potential of 
the organic residues, batch experiments were designed in accordance 












Figure 2. Batch experiments 
 
Different operating conditions were tested: temperature (35 vs 16oC), 
substrate organic carbon loading (0.3, 0.8 & 1.6g) and pharmaceutical 
concentrations (Table 1). Initial preliminary work evaluated caffeine, 
carbamazepine and lidocaine individually; subsequently combinations 
of all pharmaceuticals were chosen based on recent literature. With 
high concentrations primarily found in hospital WW. Polyethylene 











Table 1. Low and high pharmaceutical mixtures studied 
RESULTS – Individual compounds 
Degradation rates and accumulated biogas productions at 35 ⁰C of all samples are 
shown in Figure 3. The test was considered valid as the reference item was degraded 













Figure 3. Accumulated biogas productions and anaerobic degradation rates of samples at 35 oC. Values 
represent means ± SD (n=3) 
RESULTS – Pharmaceutical mixtures 
Preliminary results for the pharmaceutical mixtures, based on 10 days incubation, 
are presented in Figure 4. Again biodegradation rates and accumulated biogas 

















Figure 4. Accumulated biogas production and anaerobic degradation rates of samples after 10 days at 
35 oC. Values represent means ± SD (n=3) 
DISCUSSIONS 
• Higher organic loading rates (0.8 and 1.6),  produced higher biogas production. 
However, degradation rates are similar for all OLR (39.3, 43.3 and 41.1% for 0.3, 
0.8 and 1.6 ratios respectively). Thus, anaerobic microorganisms do not seem to 
be affected at high OLR.  
• When present individually caffeine, carbamazepine and lidocaine did not appear 
to effect the degradation of samples.  
• Observations during the initial incubation of all pharmaceuticals combined have 
indicated possible inhibition at high concentrations, whilst low concentrations 
have appeared to positively influence biogas production.   
 
FUTURE WORK 
It is unclear whether the early findings using the pharmaceutical mixture are a result 
of a single compound or a number of combinations. Future work will investigate the 
effects of individual and grouped pharmaceuticals to assess the most problematic.  
Once a suitable concentration has been chosen, all pharmaceuticals will be 















































































































Atenolol 0.35 6.03 
Bezafibrate 0.035 6.0 
Caffeine 0.68 54.7 
Ciprofloxacin 0.017 17.5 
Clarithromycin 0.04 8.0 
Carbamazepine 0.16 0.82 
Erythromycin 0.014 2.3 
Naproxen  1.1 27.4 
Lidocaine 0.07 0.77 
Propanolol 0.03 0.51 
Simvastatin 0.9 8.5 
